Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bluebird Bio (BLUE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise

With tax reform on the horizon, the biotech sector is expected to witness a surge in M&A deals. Here is a look at Juno (JUNO) and two other biotech stocks that could be on the acquisition radar.

BLUE : 208.95 (+22.09%)
JNJ : 140.44 (-0.11%)
INCY : 97.28 (+0.72%)
GILD : 75.81 (+2.14%)
AMGN : 177.25 (+1.05%)
JUNO : 51.86 (-11.58%)
SNY : 43.54 (+0.69%)
Thinking about investing in bluebird bio Inc., Celgene, Gilead Sciences, SunPower or Waste Management?

CHICAGO , Dec. 11, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLUE, CELG, GILD, SPWR, and WM.

CELG : 108.47 (+2.24%)
BLUE : 208.95 (+22.09%)
WM : 85.46 (+1.05%)
GILD : 75.81 (+2.14%)
SPWR : 9.40 (+12.71%)
Thinking about investing in bluebird bio Inc., Celgene, Gilead Sciences, SunPower or Waste Management?

InvestorsObserver issues critical PriceWatch Alerts for BLUE, CELG, GILD, SPWR, and WM.

CELG : 108.47 (+2.24%)
BLUE : 208.95 (+22.09%)
WM : 85.46 (+1.05%)
GILD : 75.81 (+2.14%)
CELGZ : 1.07 (+2.88%)
SPWR : 9.40 (+12.71%)
bluebird bio Presents Updated Data from HGB-205 Study of LentiGlobin(TM) Gene Therapy in Patients with Severe Sickle Cell Disease and Transfusion-Dependent B-Thalassemia at American Society of Hematology Annual Meeting

--- Ongoing transfusion independence up to 3.8 years in patients with transfusion-dependent B-thalassemia; three of four patients have normal or near-normal total hemoglobin levels -

BLUE : 208.95 (+22.09%)
bluebird bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin(TM) Gene Therapy in Severe Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

--- Plerixafor mobilization and apheresis cell collection for LentiGlobin manufacture now implemented in the study, first patient treated with this method had a peripheral VCN of 2.5 copies/diploid genome...

BLUE : 208.95 (+22.09%)
bluebird bio Presents New Data from Clinical Studies of LentiGlobin(TM) Gene Therapy in Transfusion-Dependent B-Thalassemia at American Society of Hematology Annual Meeting

--- 90% patients with non-B(0)/B(0) genotypes free of transfusions in Phase 1/2 Northstar (HGB-204) study after up to three-year follow up, demonstrating durable treatment effect in TDT -

BLUE : 208.95 (+22.09%)
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting

--Complete Response (CR) rate of 56% observed in patients in active dose cohorts

CELG : 108.47 (+2.24%)
BLUE : 208.95 (+22.09%)
CELGZ : 1.07 (+2.88%)
Gilead Sciences to Acquire Cell Design Labs for $567 Million

Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.

CELG : 108.47 (+2.24%)
BLUE : 208.95 (+22.09%)
NVS : 83.94 (-0.02%)
GILD : 75.81 (+2.14%)
bluebird bio and TC BioPharm Announce Strategic Collaboration to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy

bluebird bio, Inc. (Nasdaq: BLUE) and Scottish immunotherapy company TC BioPharm, Ltd. (TCB) today announced a strategic collaboration and license agreement focused on gamma delta...

BLUE : 208.95 (+22.09%)
bluebird bio Acquires Manufacturing Facility in North Carolina and Executes Multiple Global Supply Agreements to Enhance Ability to Deliver Gene Therapies to Patients

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene and cell therapies for severe genetic diseases and T cell-based...

BLUE : 208.95 (+22.09%)
CAR-T Therapy Space 2017 Progress Report

Given the vast potential of the CAR T therapy space and two recent approvals, biotech companies are leaving no stone unturned to develop their pipeline candidates.

CELG : 108.47 (+2.24%)
BLUE : 208.95 (+22.09%)
NVS : 83.94 (-0.02%)
ZIOP : 4.43 (-0.45%)
GILD : 75.81 (+2.14%)
JUNO : 51.86 (-11.58%)
New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of bluebird bio, Inc. (NASDAQ:BLUE),...

GCO : 30.20 (+1.00%)
POR : 48.50 (-0.37%)
BLUE : 208.95 (+22.09%)
ARAY : 4.90 (+0.61%)
REI : 13.68 (+2.24%)
CSL : 113.22 (-0.79%)
New Research Coverage Highlights bluebird bio, Accuray, Carlisle Companies, Genesco, Portland General Electric, and Ring Energy -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of bluebird bio, Inc. (NASDAQ:BLUE),...

GCO : 30.20 (+1.00%)
POR : 48.50 (-0.37%)
BLUE : 208.95 (+22.09%)
ARAY : 4.90 (+0.61%)
REI : 13.68 (+2.24%)
CSL : 113.22 (-0.79%)
Cancer Space Update: Label Expansion for Three Major Drugs

This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

AVEO : 3.03 (+3.06%)
CELG : 108.47 (+2.24%)
AZN : 33.14 (+1.22%)
BLUE : 208.95 (+22.09%)
MRK : 56.52 (+1.71%)
RHHBY : 30.3400 (+0.40%)
PFE : 36.08 (+0.95%)
Celgene CAR-T Therapy Gets Breakthrough Therapy Designation

FDA grants Breakthrough Therapy Designation to Celgene's (CELG) chimeric antigen receptor T-cell (CAR-T) therapy candidate, bb2121.

CELG : 108.47 (+2.24%)
BLUE : 208.95 (+22.09%)
NVS : 83.94 (-0.02%)
GILD : 75.81 (+2.14%)
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma

Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen...

CELG : 108.47 (+2.24%)
BLUE : 208.95 (+22.09%)
CELGZ : 1.07 (+2.88%)
bluebird bio Announces First Patient Treated in Northstar-3 (HGB-212), Phase 3 Study of LentiGlobin(TM) in Patients with Transfusion-Dependent B-Thalassemia (TDT) and B(0)/B(0) Genotype

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies...

BLUE : 208.95 (+22.09%)
Biotech on the Brink!

This post Biotech on the Brink! appeared first on Daily Reckoning . It’s do-or-die for biotech stocks. Today, Greg Guenthner sets the tone for the final weeks of 2017… The post Biotech on the...

BLUE : 208.95 (+22.09%)
IBB : 106.71 (+0.60%)
GILD : 75.81 (+2.14%)
REGN : 380.93 (+0.04%)
AMGN : 177.25 (+1.05%)
XBI : 83.93 (-0.20%)
Small Cap ETFs in Focus as Domestic Growth Picks Momentum

U.S. small cap ETFs pick up on rising growth and upbeat economic performance.

MKSI : 92.60 (-1.70%)
IJR : 76.23 (-0.03%)
BLUE : 208.95 (+22.09%)
EXAS : 52.28 (-2.88%)
CDW : 70.07 (+0.44%)
TFX : 251.49 (-0.50%)
ALE : 78.95 (-0.48%)
VB : 146.93 (+0.07%)
LITE : 52.75 (+6.35%)
IWM : 151.67 (+0.17%)
TTWO : 106.59 (-0.21%)
Small Cap ETFs in Focus as Domestic Growth Picks Momentum

U.S. small cap ETFs pick up on rising growth and upbeat economic performance.

MKSI : 92.60 (-1.70%)
IJR : 76.23 (-0.03%)
BLUE : 208.95 (+22.09%)
EXAS : 52.28 (-2.88%)
CDW : 70.07 (+0.44%)
TFX : 251.49 (-0.50%)
ALE : 78.95 (-0.48%)
VB : 146.93 (+0.07%)
LITE : 52.75 (+6.35%)
IWM : 151.67 (+0.17%)
TTWO : 106.59 (-0.21%)

Van Meerten Stock Picks

5 Great Large Caps
Today I wanted to find 5 Large Caps that still had some upside potential.
ALL -0.53 , AMP -0.85 , LB +0.30 , AXP +0.17 , AKAM +0.25
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Mar E-mini S&Ps ( ESH18 +0.09%) this morning are up +0.08% and European stocks are down -0.12% . Most global stocks markets moved higher ahead of central bank meetings this week from the Fed, ECB and BOE. U.S.... Read More

Chart of the Day

Chart of the Day

Viking Therapeutics (VKTX) is the Barchart Chart of the Day.  The biopharmaceutical company has a Trend Spotter, a Weighted Alpha of 206.52+ and gained 254.95% in the last year
Read More

Brugler Ag Report

Today's Commentary

Corn futures are 1 to 2 cents lower this morning, with speculative attention drawn toward the beginning of bitcoin futures trading (+26% at one point overnight!). They saw gains of 1/4 to 1 1/4 cents on Friday, but nearby Dec was 1.38% for the week. ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.